Valeant Appoints William Humphries As EVP, Dermatology

(RTTNews) - Valeant Pharmaceuticals International, Inc. (VRX, VRX.TO) announced that William Humphries has been appointed Executive Vice President, Dermatology, effective January 2, 2017. Humphries will join Valeant's Executive Committee, reporting directly to Joseph C. Papa, Valeant's Chairman and Chief Executive Officer.

Mr. Humphries has nearly 30 years of experience in the dermatology and specialty pharmaceuticals industry. He joins Valeant from Merz GmbH & Co. KGaA, where he most recently served as CEO of its North America business. Prior to Merz, he served as President of Stiefel, a leader in global dermatology and skin health that is now a subsidiary of GlaxoSmithKline, and held multiple senior roles at Allergan, Inc., including Vice President of the U.S. skincare business.

Valeant also announced today that Anne Whitaker, EVP & Company Group Chairman has decided to leave the Company on January 13, 2017.

Rob Rosiello will also depart the Company on December 31, 2016. Rob previously served as the Valeant CFO from July 2015 through August 2016 and has successfully transitioned the role to our new CFO, Paul Herendeen.

Ari Kellen, EVP & Company Group Chairman will also depart Valeant on December 31, 2016.

Dr. Kellen and Mr. Rosiello will continue to serve as consultants on an ongoing basis.